Posts in the “Clinical Trials Clinical Trials” category:

New Kind of Trial Aims to Speed Cancer Drug Development

Posted by Samantha Powell on April 16th, 2014 |

Date: 4/16/14 Outlet Full Name: Reuters Author: Ben Hirschler http://www.reuters.com/article/2014/04/16/us-cancer-trials-idUSBREA3F22520140416 Scientists and drugmakers are pioneering a new kind of clinical trial that changes the way cancer drugs are studied, potentially cutting both the time and cost of bringing them to market. Instead of testing one drug at a time, a novel lung cancer study announced […]

GlaxoSmithKline Throws in Towel on Lung Cancer Vaccine Trial

Posted by Samantha Powell on April 2nd, 2014 |

Date: 4/2/14 Outlet Full Name: Reuters Author: Ben Hirschler http://www.reuters.com/article/2014/04/02/us-gsk-cancer-idUSBREA310E420140402 GlaxoSmithKline Plc (GSK) has stopped a high-profile clinical trial using a novel vaccine to fight lung cancer after deciding it will not be possible to find a sub-group of patients who might benefit. The decision comes less than two weeks after GSK said the MAGE-A3 […]

Novartis Says Lung Cancer Patients Respond to Drug in Study

Posted by Samantha Powell on March 27th, 2014 |

Date: 3/27/14 Outlet Full Name: Reuters Author: Katharina Bart http://www.reuters.com/article/2014/03/27/us-novartis-ldk-idUSBREA2Q0CN20140327 Novartis said late on Wednesday that a majority of patients given a development drug against non-small cell lung cancer had responded to the treatment, according to study results published in the New England Journal of Medicine. The Basel-based drugmaker’s LDK378 has been declared a “breakthrough […]

Pfizer’s Xalkori Shines as First-Line Lung Cancer Therapy

Posted by Samantha Powell on March 26th, 2014 |

Date: 3/26/14 Outlet Full Name: Pharma Times Author: Kevin Grogan http://www.pharmatimes.com/article/14-03-26/Pfizer_s_Xalkori_shines_as_first-line_lung_cancer_therapy.aspx Pfizer has reported positive late-stage data on a trial of Xalkori compared to chemotherapy in previously-untreated lung cancer patients with a specific gene mutation. The Phase III study of Xalkori (crizotinib) met its primary objective of significantly prolonging progression-free survival in previously-untreated patients with […]

Ariad Begins Trial of Lung Cancer Drug, Says Side Effects Will Be Different From Iclusig

Posted by Samantha Powell on March 24th, 2014 |

Date: 3/24/14 Outlet Full Name: Boston Business Journal Author: Don Seiffert http://www.bizjournals.com/boston/blog/bioflash/2014/03/ariad-begins-trial-of-lung-cancer-drug-says-side.html?page=all Ariad Pharmaceuticals has begun a trial to study a treatment for the most common form of lung cancer, and while the drug works the same way as the biotech firm’s first approved drug, Iclusig, the company doesn’t expect it to show similar side […]

ASCO: ‘Smaller, smarter’ cancer trials will yield more meaningful results

Posted by Samantha Powell on March 24th, 2014 |

Date: 3/24/14 Outlet Full Name: Healio Hematology/Oncology Author: Ellis LM http://www.healio.com/hematology-oncology/practice-management/news/online/%7Bdbf305e6-0b11-48aa-a214-f47c9874b716%7D/asco-smaller-smarter-cancer-trials-will-yield-more-meaningful-results ASCO recently released new recommendations designed to increase the likelihood of “clinical meaningful outcomes” in trials for advanced pancreatic, lung, breast and colon cancers. The recommendations — developed by the ASCO Cancer Research Committee in conjunction with other experts and patient advocates, and published […]

Glaxo’s Immunotherapy Fails to Help Lung Cancer Patients

Posted by Samantha Powell on March 20th, 2014 |

Date: 3/20/14 Outlet Full Name: Bloomberg News Author: Allison Connolly, Makiko Kitamura http://www.bloomberg.com/news/2014-03-20/glaxo-s-cancer-medicine-fails-to-meet-goal-of-trial.html An experimental GlaxoSmithKline Plc (GSK) product didn’t work in a lung cancer study, the second time the medicine failed an advanced test against cancer. The therapy known as MAGE-A3 didn’t help patients with non-small cell lung cancer live longer without the disease […]

UC Davis Researchers Have Found Potential Lung Cancer Vaccine Shows Renewed Promise

Posted by Samantha Powell on March 20th, 2014 |

Date: 3/20/14 Outlet Full Name: PR Web Author: No author http://www.prweb.com/releases/2014/03/prweb11690301.htm Researchers at UC Davis have found that the investigational cancer vaccine tecemotide, when administered with the chemotherapeutic cisplatin, boosted immune response and reduced the number of tumors in mice with lung cancer. The study also found that radiation treatments did not significantly impair the […]

Lung Cancer Trials Soften Endpoint

Posted by Samantha Powell on March 3rd, 2014 |

taille hollister femme News Headline: Lung Cancer Trials Soften Endpoint Date: 3/3/14 Outlet Full Name: Med Page Today Author: Charles Bankhead http://www.medpagetoday.com/HematologyOncology/LungCancer/44584 Use of overall survival as the primary endpoint has decreased significantly in clinical trials of advanced lung cancer, as has the magnitude of clinically relevant improvement, a review of 200 studies showed. Before […]

Lilly Lung Cancer Drug Performs in Tests

Posted by Samantha Powell on February 19th, 2014 |

News Headline: Lilly Lung Cancer Drug Performs in Tests Date: 2/19/14 Outlet Full Name: Indianapolis Star Author: Jeff Swiatek http://www.indystar.com/story/money/2014/02/19/lilly-lung-cancer-drug-performs-in-tests/5607235/ A lung cancer drug in testing by Eli Lilly and Co. performed well in a late-phase patient trial. The Indianapolis drug maker said today that its experimental drug ramucirumab plus standard chemotherapy helped patients with […]